Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug ALTO-100 during the class period from February 2, 2024, to October 22, 2024 [2][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Alto securities during the specified class period [2]. - Investors have until September 19, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. - The complaint alleges that the Offering Documents for the IPO were negligently prepared and that key information about ALTO-100's effectiveness was not disclosed [3]. Group 2: Impact on Stock Price - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial for treating Major Depressive Disorder (MDD), leading to a significant stock price drop [4]. - Following the announcement, Alto's stock price fell by $10.17 per share, or 69.99%, closing at $4.36 per share on October 23, 2024 [4]. Group 3: Contact Information - Investors who suffered losses or have questions regarding the lawsuit can contact Bragar Eagel & Squire, P.C. for more information [5][8].
ALTO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Contact the Firm